The approved pills changed the maths
Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.
Updated 2026-09-18
Two oral GLP-1s were approved either side of the new year, and the distinction between them is pharmacological rather than commercial.
Both start at $149 a month self-pay. That is more than the cheapest compounded programmes — SuperHealthy Rx is $85 and Trimi is $125 — but it is less than the majority of what we track, and it buys a product the FDA has actually reviewed.
Peptide versus small molecule
Oral semaglutide is a peptide, which is why it needs absorption enhancers and strict dosing conditions. Orforglipron is a non-peptide small molecule — the first approved for weight management — which is what removes the food and water restrictions. Both are FDA-approved finished drug products, which is the category distinction that matters against anything compounded.
Wegovy pill (oral semaglutide)
Approved late December 2025, launched in the US on 5 January 2026. The first oral GLP-1 approved for weight management — the same active ingredient as the Wegovy injection, taken as a daily tablet.
Self-pay from $149/month for the 1.5 mg starting dose. The 4 mg dose was offered at $149/month through 15 April 2026 and $199/month after, with the highest doses around $299/month.
Available through LillyDirect-style manufacturer channels and telehealth partners including Ro, GoodRx Care Direct and Walgreens.
Foundayo (orforglipron)
FDA approved 1 April 2026. The first oral small-molecule, non-peptide GLP-1 receptor agonist approved for weight management. Unlike oral semaglutide it is not a peptide, so it has no food-and-water timing restrictions of the same kind.
Self-pay from $149/month for the lowest 0.8 mg dose, about $199/month at 2.5 mg, and roughly $299-$349/month at higher doses.
Self-pay through LillyDirect, with telehealth partners including Ro.
Who should actually consider switching
- Anyone paying more than about $200 a month for a compounded injection. You are now paying a premium for a non-approved product, which is a strange place to be.
- Anyone who never wanted to inject. This is the obvious one — a genuine approved alternative now exists at a sane price.
- Anyone uneasy about the compounding rules. The 2026 regulatory direction is not friendly to compounded GLP-1s; see is compounded still legal.
- Medicare beneficiaries. From July 2026 you may be able to get an approved GLP-1 for $50 a month — see the Medicare programme.
Who probably should not
If you are already on Trimi or SuperHealthy Rx at under $130 a month, tolerating it well and getting results, the approved pills cost more. That is a real reason to stay put. The comparison changes if your programme raises prices or your dose pushes you into a higher tier.
Whichever direction you are considering, it is a conversation with a prescriber rather than a purchase decision. Both drugs have contraindications, and switching between them is not simply swapping one box for another.
Read next
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- Reading your label
What each line on the vial and the paperwork means, and the four things to check the moment the box arrives.
- What "compounded" actually means
Not a knock-off, not an approved drug. A specific legal category with specific consequences — explained without the scare tactics or the sales pitch.
- Who should not take these
The contraindications and interactions an online questionnaire may not catch. Worth reading before you fill one in.
- Brand-name or compounded?
The difference is not quality claims either way — it is what has been reviewed, by whom, and what recourse you have.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure